Changing Landscape of NSCLC with Targeted Therapies and Immunotherapy

Released On
December 8, 2020

Expires On
December 8, 2021

Media Type

Completion Time
75 minutes

Medical Oncologists, Thoracic Surgeons, Radiation Oncologists, Nurse Practitioners, Physician Assistants, Nurses

Non-small Cell Lung Cancer

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by CancerNet, LLC and Amedco, LLC.


Supported by an independent educational grant from Takeda Oncology.

Credit Available

  • Physicians — maximum of 1.25 AMA PRA Category 1 Credit(s)
  • Nurses — 1.25 Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of medical oncologists, thoracic surgeons, radiation oncologists, nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment of non-small cell lung cancer (NSCLC) patients.

Program Overview

This activity will cover topics on the diagnosis, treatment, and management of patients with non-small cell lung cancer.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Select first-line therapy for patients with EGFR-, EGFR T790M-positive, and ALK-positive NSCLC based on clinical factors and molecular subtyping
  • Outline mechanisms of acquired resistance to EGFR- EGFR T790M-TKI and ALK-positive therapy and selection of sequential treatment in these patients
  • Outline the optimal use of immune checkpoint inhibitors (ICIs) and combination approaches in NSCLC
  • Implement strategies to assess, recognize, and manage immune-related adverse events (IRAES) in patients treated with ICIs.


Mark A. Socinski, MD

Medical Oncologist and Executive Medical Director
Florida Hospital Cancer Institute and AdventHealth Cancer Institute
Orlando, FL

Charu Aggarwal, MD, MPH

Leslye M. Heisler Associate Professor of Medicine
Division of Hematology/Oncology
University of Pennsylvania
Philadelphia, PA

Accreditation Statement


In support of improving patient care, this activity has been planned and implemented by Amedco LLC and CancerNet. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Credit Designation

Credit Designation Statement – Amedco LLC designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™ for physicians and 1.25 hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest and have been resolved (C7 SCS 6.1-6.2, 6.5). All individuals in a position to control the content of CE are listed below.

All individuals in a position to control the content of CE are listed on the website. If their name is not listed below, they disclosed that they had no financial relationships with a commercial interest.

Faculty Disclosures

Mark A. Socinski, MD

  • Consulting/advisory committee: AstraZeneca, Bayer, Bristol-Myers Squibb, Genentech, Guardant, Merck
  • Speaker's Bureau
  • : AstraZeneca, Bayer, Bristol-Myers Squibb, Genentech, Guardant, Merck
  • Research Funding: AstraZeneca, Genentech, Novartis, Spectrum

Charu Aggarwal, MD, MPH Charu Aggarwal, MD, MPH

  • Consulting/advisory committee: AstraZeneca, Bristol-Myers Squibb, Celgene, Eli Lilly, Genentech, Merck
  • Research Funding: AstraZeneca, Incyte, Merck, Novartis, Xencor

Planners and Managers Disclosures

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME webcast:

  • Kamatham A. Naidu, PhD (CancerNet, LLC), has no relevant financial relationships.
  • Brian Waggoner (CancerNet, LLC) has no relevant financial relationships to disclose.
  • Sheryl Morgan (Amedco) has no relevant financial relationships to disclose.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Submit the evaluation form.
Certificates will be emailed to the participant


Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

Amedco and CancerNet require that faculty participating in any CME/CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.X


Amedco makes every effort to develop CME/CE activities that are scientifically based.

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME/CE questions, please contact: Amedco at:

For questions regarding content, please contact: CancerNet at